Science Current Events | Science News | Brightsurf.com
 

New vaccine strategy better protects high-risk cancer patients from flu

December 07, 2015

New Haven, Conn. - Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death. Even though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.

The Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later. The high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.

The booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).

"Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group patients at high risk for infection," Branagan said. "We hope to confirm these results in a larger prospective randomized trial that is underway now at Yale during the 2015-2016 flu season. We suspect this strategy could benefit other cancer patient populations."

###

This study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.

Yale University


Related Vaccine Strategy Current Events and Vaccine Strategy News Articles


Research behind global switch to new polio vaccine strategy released in the Lancet
A groundbreaking study released today shows that a single injectable dose of inactivated polio vaccine (IPV) along with bivalent oral polio vaccine could protect up to 90 percent of children from polio and strengthen community protection against the disease.

Findings in humans provide encouraging foundation for upcoming AIDS vaccine clinical trial
Some people infected with HIV naturally produce antibodies that effectively neutralize many strains of the rapidly mutating virus, and scientists are working to develop a vaccine capable of inducing such "broadly neutralizing" antibodies that can prevent HIV infection.

No Hib booster needed by vaccinated infants in Kenya
A 15-year study carried out in Kilifi, Kenya and funded by the Wellcome Trust and Gavi, the Vaccine Alliance has shown that there is no need to give a Hib booster to toddlers to extend immunity into later childhood.

Swine flu outbreak in India raises concern
Since December, an outbreak of swine flu in India has killed more than 1,200 people, and a new MIT study suggests that the strain has acquired mutations that make it more dangerous than previously circulating strains of H1N1 influenza.

A vaccine directed against tumor blood vessels suppress tumor growth and metastasis
In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumor vessels can reduce tumor burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer.

Novel vaccine approach to human cytomegalovirus found effective
An experimental vaccine against human cytomegalovirus (CMV) infection, which endangers the developing fetus, organ transplant recipients, patients with HIV and others who have a weakened immune system, proved safe and more effective than previous vaccines developed to prevent infection by the ubiquitous virus.

Successful results against human leishmaniasis with a more efficient and economic vaccine
A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis. The vaccine was tested with the best animal model existing, the golden hamster, and can be produced at low costs by using insect larvae.

New vaccine for nicotine addiction
Researchers at Weill Cornell Medical College have developed and successfully tested in mice an innovative vaccine to treat nicotine addiction.

Moffitt Cancer Center Researchers Develop and Test New Anti-Cancer Vaccine
Researchers at Moffitt Cancer Center have developed and tested in mice a synthetic vaccine and found it effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others.

Genetics study reveals how bacteria behind serious childhood disease evolve to evade vaccines
Genetics has provided surprising insights into why vaccines used in both the UK and US to combat serious childhood infections can eventually fail.
More Vaccine Strategy Current Events and Vaccine Strategy News Articles

  Influenza: Virus, Vaccine and Strategy (Sandoz Institute publication)
by Philip Selby (Editor)




Protecting the Frontline in Biodefense Research: The Special Immunizations Program

Protecting the Frontline in Biodefense Research: The Special Immunizations Program
by National Research Council (Author), Division on Earth and Life Studies (Author), Board on Life Sciences (Author), Committee on Special Immunizations Program for Laboratory Personnel Engaged in Research on Countermeasures for Select Agents (Author)


The U.S. Army's Special Immunizations Program is an important component of an overall biosafety program for laboratory workers at risk of exposure to hazardous pathogens. The program provides immunizations to scientists, laboratory technicians and other support staff who work with certain hazardous pathogens and toxins. Although first established to serve military personnel, the program was expanded through a cost-sharing agreement in 2004 to include other government and civilian workers, reflecting the expansion in biodefense research in recent years. Protecting the Frontline in Biodefense Research examines issues related to the expansion of the Special Immunizations Program, considering the regulatory frameworks under which the vaccines are administered, how additional vaccines might be...

Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military

Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military
by Institute of Medicine (Author), Medical Follow-Up Agency (Author), Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military (Author), Salem Fisseha (Editor), Susan Thaul (Editor), Stanley M. Lemon (Editor)


Infectious diseases continue to pose a substantial threat to the operational capacity of military forces. Protecting Our Forces reviews the process by which the U.S. military acquires vaccines to protect its warfighters from natural infectious disease threats. The committee found that poorly aligned acquisition processes and an inadequate commitment of financial resources within the Department of Defense vaccine acquisition process â€" rather than uncleared scientific or technological hurdles â€" contribute to the unavailability of some vaccines that could protect military personnel and, implicitly, the welfare and security of the nation. Protecting Our Forces outlines ways in which DoD might strengthen its acquisition process and improve vaccine availability. Recommendations, which...

Recombinant DNA Vaccines: Rationale and Strategy

Recombinant DNA Vaccines: Rationale and Strategy
by Richard Isaacson (Editor)


Book by

Mimotope Vaccines against Tumor Antigens: A Strategy for Active Immunotherapy?

Mimotope Vaccines against Tumor Antigens: A Strategy for Active Immunotherapy?
by Agnes Boltz (Author)


Cancer is an important public health concern since it is the second leading cause of death in the developed world. Previous treatments, such as surgical tumor resection, radio- or chemotherapy also harm healthy tissue and, therefore, are limited by these adverse effects. In contrast, immunotherapy using the endogenous defense mechanisms poses a specific, nontoxic and mild therapy. But how can we approach this advantageous new therapy? This book gives us an introductory review of the role of the immune system in recognition and prevention of cancer as well as of current research strategies. Furthermore, the author provides a detailed guide for creating so called mimotopes for the carcinoembryonic antigen (CEA), which is a possible basis for establishing active immunotherapy, i.e. cancer...

  Molecular Strategy for the Construction of a Genetically Engineered Vaccine for Venezuelan Equine Encephalitis Virus
by Robert E. Johnston (Author)




  Protection Against Dengue Virus by Non-Replicating and Live Attenuated Vaccines Used Together in a Prime Boost Vaccination Strategy
by Monika Simmons (Author)




HIV/Vaccine Needs - Procs of the Intl Seminar on Planetary Emergencies, 24th Session

HIV/Vaccine Needs - Procs of the Intl Seminar on Planetary Emergencies, 24th Session
by Richard C. Ragaini (Author), Ragaini Richard (Author)


http://www.worldscientific.com/worldscibooks/10.1142/4472

Protecting Our Forces:: Improving Vaccine Acquisition and Availability in the U.S. Military 1st edition by Committee on a Strategy for Minimizing the Impact of Natural (2002) Paperback

Protecting Our Forces:: Improving Vaccine Acquisition and Availability in the U.S. Military 1st edition by Committee on a Strategy for Minimizing the Impact of Natural (2002) Paperback
by National Academies Press (Publisher)




Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military 1st Edition by Military, Committee on a Strategy for Minimizing the Impact published by National Academies Press

Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military 1st Edition by Military, Committee on a Strategy for Minimizing the Impact published by National Academies Press
by National Academies Press (Publisher)




© 2017 BrightSurf.com